Concord Wealth Partners Vaxart, Inc. Transaction History
Concord Wealth Partners
- $591 Million
- Q3 2024
A detailed history of Concord Wealth Partners transactions in Vaxart, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 75 shares of VXRT stock, worth $43. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75
Previous 75
-0.0%
Holding current value
$43
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VXRT
# of Institutions
110Shares Held
37.6MCall Options Held
188KPut Options Held
180K-
Sio Capital Management, LLC New York, NY13.6MShares$7.89 Million6.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$5.84 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.97MShares$2.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.54MShares$1.48 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.77MShares$1.03 Million0.0% of portfolio
About Vaxart, Inc.
- Ticker VXRT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,506,000
- Market Cap $73.4M
- Description
- Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...